1-(4-氯苯甲酰基)-4-哌啶羧酸 | 379724-54-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-氯苯甲酰基)-4-哌啶羧酸
• 中文别名: 1-(4-氯苯甲酰)4-哌啶甲酸；1-(4-氯苯甲酰)哌啶-4-羧酸；1-[(4-氯苯基)-氧代甲基]-4-哌啶-1-羧酸；1-(4-氯苯基)羰基哌啶-4-羧酸
• 英文名称: 1-(4-chlorobenzoyl)piperidine-4-carboxylic acid
• CAS: 379724-54-6
• 化学式: C₁₃H₁₄ClNO₃
• mdl: MFCD03014156
• 分子量: 267.712
• InChiKey: FGLQAKJRFPNIJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-(4-氯苯甲酰基)-4-哌啶羧酸 在 silver nitrate 、 Selectfluor 作用下， 以 水 、 丙酮 为溶剂， 反应 10.0h， 以60%的产率得到(4-chlorophenyl)(4-fluoropiperidin-1-yl)methanone
  参考文献：
  名称：

  脂肪族羧酸在水溶液中的银催化脱羧氟化

  摘要：

  尽管氟化化合物已在化学和材料行业中得到广泛应用，但一般和特定于站点的 C(sp(3))-F 键的形成仍然是一项具有挑战性的任务。我们在此报告，在 AgNO(3) 的催化作用下，各种脂肪族羧酸在水溶液中使用 SELECTFLUOR(®) 试剂进行有效的脱羧氟化，从而在温和条件下以令人满意的产率合成相应的烷基氟化物。这种自由基氟化方法不仅高效通用，而且具有化学选择性和官能团相容性，因此在氟化分子的合成中具有很高的实用性。对于这种催化氟脱羧，提出了一种涉及 Ag(III) 介导的单电子转移，然后是氟原子转移的机制。

  DOI：

  10.1021/ja3048255
• 作为产物：
  描述：

  4-哌啶甲酸 、 4-氯苯甲酰氯 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 1-(4-氯苯甲酰基)-4-哌啶羧酸
  参考文献：
  名称：

  Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423

  摘要：

  We recently identified bis(amide) CCG-1423 (1) as a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. An initial structure-activity relationship study focusing on bioisosteric replacement of the amides and conformational restriction identified two compounds, 4g and 8, with improved selectivity for inhibition of RhoA/C-mediated gene transcription and attenuated cytotoxicity relative to 1. Both compounds were also capable of inhibiting cell invasion with equal efficacy to 1 but with less attendant cytotoxicity. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.056

文献信息

• Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease
  作者：Jianfeng Mou、Songliang Wu、Zhi Luo、Fengying Guo、Haiying He、Jianhua Wang、Fusen Lin、Fengxun Guo、Jianping Sun、Liang Shen、Minggao Zeng、Chuan Wang、Deming Xu、Zhengxian Gu、Xin Tian、Aiming Zhang、Hongjiang Xu、Ling Yang、Xiquan Zhang、Jian Li、Shuhui Chen

  DOI：10.1016/j.bmcl.2018.04.002

  日期：2018.6

  A series of caspase inhibitors containing γ-amino acid moiety have been synthesized. A systemic study on their structure-activity relationship of anti-apoptotic cellular activity is presented. These efforts led to the discovery of compound 20o as a potent caspase inhibitor, which demonstrated preclinical ameliorating total bilirubin efficacy with a significantly improved pharmacokinetic profile.

  已经合成了一系列含有γ-氨基酸部分的胱天蛋白酶抑制剂。对其抗凋亡细胞活性的构效关系进行了系统的研究。这些努力导致了化合物20o作为有效的半胱天冬酶抑制剂的发现，证明了临床前改善总胆红素功效并显着改善了药代动力学。
• Silver-Catalyzed Decarboxylative Trifluoromethylation of Aliphatic Carboxylic Acids
  作者：Xinqiang Tan、Zhonglin Liu、Haigen Shen、Pei Zhang、Zhenzhen Zhang、Chaozhong Li

  DOI：10.1021/jacs.7b07944

  日期：2017.9.13

  The silver-catalyzed decarboxylative trifluoromethylation of aliphatic carboxylic acids is described. With AgNO3 as the catalyst and K2S2O8 as the oxidant, the reactions of aliphatic carboxylic acids with (bpy)Cu(CF3)3 (bpy = 2,2'-bipyridine) and ZnMe2 in aqueous acetonitrile at 40 °C afford the corresponding decarboxylative trifluoromethylation products in good yield. The protocol is applicable to

  描述了银催化的脂肪族羧酸的脱羧三氟甲基化。以 AgNO3 为催化剂，K2S2O8 为氧化剂，脂肪族羧酸与 (bpy)Cu(CF3)3（bpy = 2,2'-联吡啶）和 ZnMe2 在 40 °C 的乙腈水溶液中反应，提供相应的脱羧三氟甲基化产量良好的产品。该协议适用于各种伯和仲烷基羧酸，并具有广泛的官能团兼容性。机理研究揭示了 -Cu(CF3)3Me 的中间体，它经过还原消除和随后的氧化，得到 Cu(CF3)2 作为负责烷基三氟甲基化的活性物质。
• METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION
  申请人：Neubig Richard

  公开号：US20120252792A1

  公开（公告）日：2012-10-04

  The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.

  本发明提供了抑制Rho GTPase家族成员的方法、组合物和试剂盒。具体来说，本发明提供了抑制RhoA和/或RhoC转录信号的方法、组合物和试剂盒。本发明可用于治疗Rho介导的疾病状态（例如肿瘤转移、炎症、炎症性疾病）、Rho介导的生物条件以及细胞信号研究。
• [EN] METHODS AND COMPOSITIONS FOR INHIBITING RHO-MEDIATED DISEASES AND CONDITIONS<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR INHIBER DES MALADIES ET DES ÉTATS À MÉDIATION PAR RHO
  申请人：UNIV MICHIGAN

  公开号：WO2011035143A2

  公开（公告）日：2011-03-24

  The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.
• Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423
  作者：Chris R. Evelyn、Jessica L. Bell、Jenny G. Ryu、Susan M. Wade、Andrew Kocab、Nicole L. Harzdorf、H.D. Hollis Showalter、Richard R. Neubig、Scott D. Larsen

  DOI：10.1016/j.bmcl.2009.11.056

  日期：2010.1

  We recently identified bis(amide) CCG-1423 (1) as a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. An initial structure-activity relationship study focusing on bioisosteric replacement of the amides and conformational restriction identified two compounds, 4g and 8, with improved selectivity for inhibition of RhoA/C-mediated gene transcription and attenuated cytotoxicity relative to 1. Both compounds were also capable of inhibiting cell invasion with equal efficacy to 1 but with less attendant cytotoxicity. (C) 2009 Elsevier Ltd. All rights reserved.